Showing 1 - 3 of 3 Hematologic Cancers
A Phase 1/2, Multicenter, Open-label Study of FT-2102 as a Single Agent and in Combination with Azacitidine or Cytarabine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation

Status: Enrolling

Investigator: Jasleen Randhawa

Study Coordinator: Ashley Towne

Phone: 346.238.2006

This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 as a single agent or in combination with azacitidine or cytarabine. The Phase 1 stage of the study is split into 2 distinct parts: a dose escalation part, which will ... Read more >

A PHASE Ib STUDY OF THE SAFETY AND

Status: Open Not Enrolling

Investigator: Sai ravi kiran Pingali

Study Coordinator: Sharell Cornett-Risher

Phone: 713.441.3250

This study will evaluate the safety, efficacy, and pharmacokinetics of atezolizumab alone and in combination with various immunomodulatory agents in patients with relapsed/refractory multiple myeloma or patients with myeloma who have measureabl ... Read more >

ASTX727 vs IV Decitabine in MDS and CMML

Status: Open Not Enrolling

Investigator: Jasleen Randhawa

Study Coordinator: Ashley Towne

Phone: 346.238.2006

Multicenter, randomized, open-label, crossover PK study of ASTX727 versus IV decitabine. Adult subjects who are candidates to receive IV decitabine will be randomized 1:1 to receive the ASTX727 tablet Daily×5 in Cycle 1 followed by IV decitabine ... Read more >